Literature DB >> 20739219

Optimising bortezomib in newly diagnosed multiple myeloma.

S Vincent Rajkumar.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20739219     DOI: 10.1016/S1470-2045(10)70199-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

Review 1.  Treatment of multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Nat Rev Clin Oncol       Date:  2011-04-26       Impact factor: 66.675

2.  In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.

Authors:  Dharminder Chauhan; Arghya Ray; Kristina Viktorsson; Jack Spira; Claudia Paba-Prada; Nikhil Munshi; Paul Richardson; Rolf Lewensohn; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2013-04-12       Impact factor: 12.531

3.  A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells.

Authors:  Arghya Ray; Durgadevi Ravillah; Deepika S Das; Yan Song; Eva Nordström; Joachim Gullbo; Paul G Richardson; Dharminder Chauhan; Kenneth C Anderson
Journal:  Br J Haematol       Date:  2016-04-20       Impact factor: 6.998

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.